
Leveraging Observational Data for Efficient CATE Estimation in Randomized Controlled Trials

Amir Asiaee
Department of Biostatistics
Vanderbilt University Medical Center
Nashville, TN 37232
amir.asiaee@vumc.org

Chiara Di Gravio
Department of Biostatistics
Vanderbilt University
Nashville, TN 37232
chiara.di.gravio@vanderbilt.edu

Yuting Mei
Data Science Institute
Vanderbilt University
Nashville, TN 37212
yuting.mei@vanderbilt.edu

Jared D. Huling
Division of Biostatistics
University of Minnesota
Minneapolis, MN 55455
huling@umn.edu

Abstract

Randomized controlled trials (RCTs) are the gold standard for causal inference, but they are often powered only for average effects, making estimation of heterogeneous treatment effects (HTEs) challenging. Conversely, large-scale observational studies (OS) offer a wealth of data but suffer from confounding bias. Our paper presents a novel framework to leverage OS data for enhancing the efficiency in estimation of conditional average treatment effects (CATEs) from RCTs, while mitigating common biases. We propose an innovative approach to combine RCTs and OS data, expanding the traditionally used control arms from external sources. The framework relaxes the typical assumption of CATE invariance across populations, acknowledging the often unaccounted systematic differences between RCT and OS participants. We demonstrate this through the special case of a linear outcome model, where the CATE is sparsely different between the two populations. The core of our framework relies on learning potential outcome means from OS data, and use them as a nuisance parameter in CATE estimation from RCT data. We further illustrate through experiments that using OS findings reduces the variance of the estimated CATE from RCTs and can decrease the required sample size for detecting HTEs.

1 Introduction

Randomized controlled trials (RCTs) are the gold standard for addressing causal questions, such as estimating heterogeneous treatment effects (HTEs) – a key area of interest in personalized decision-making. However, RCTs present significant challenges in terms of design, cost, and duration. Furthermore, due to financial and time constraints, RCTs are often limited in size and scope, which hinders their ability to detect HTEs. In contrast, large-scale observational studies (OS) provide easily accessible data from various sources, such as administrative databases, cohort studies, biobanks, and electronic health records. Yet, it is well known that causal effects estimation in OS is impossible without relying on untestable assumptions (e.g., unconfoundedness). As a result, recent trends have emerged to combine both data types in order to mitigate biases in causal effect estimation from OS or enhance the efficiency of RCT-based estimators. Successfully merging OS and RCT data holds considerable potential to advance our understanding of HTEs for a target population.

Data integration typically serves to improve the estimated causal effect for a pre-determined target population. When the source population is an RCT and the target population is an OS (with or without measured treatment and outcome), data integration corresponds to generalizing or transporting causal effects from the RCT population to the OS population [1]. This direction is well-explored in the literature and is not our focus. We refer readers to two recent comprehensive reviews on generalizability and transportability [2, 3]. In this work, we address the other direction of data integration, using OS to reduce the variance of estimated CATE from RCT and potentially decrease the required sample size for detecting HTEs.

Data integration methods aimed at increasing precision in an RCT have been discussed in the clinical trials literature since the 1976 seminal paper by Pocock [4]. Briefly, the idea is to augment the control arm in the current RCT with data from similar control arms observed in previous RCTs and/or OS. These methods refer to the borrowed data as historical controls and assume some form of exchangeability between the current RCT and the historical controls. Integration of RCTs and OS is then performed using two possible methods: static borrowing [5, 6] which account for the external data as if they were part of the current RCT, and dynamic borrowing [7–10] that weight the data to be borrowed based on the degree of agreement between the current RCT and historical controls.

While the RCT literature has primarily focused on utilizing historical control arms from external sources to minimize estimation variance, the full potential of incorporating all relevant arms of observational studies remains largely unexplored, offering significant opportunities for improvement in HTE estimation. Moreover, current integration efforts (either directions) predominantly assume that the conditional average treatment effect (CATE) is invariant across populations, implying that CATE is “transportable.” However, this transportability assumption, along with its stricter forms (mean exchangeability or trial participation ignorability) [2], often does not hold true in real-world applications, particularly when unrecorded systematic differences exist between RCT and OS participants [11].

In this work, we aim to develop a framework for valid and efficient estimation of the CATE, which characterizes HTE, for the RCT population by leveraging the complementary information contained in the OS data. We introduce a general framework that reduces CATE estimation uncertainty in RCT analyses by incorporating information from OS, while relaxing the commonly required assumption of CATE invariance. We instantiate our general framework for the special case of the linear outcome model, wherein the CATE is sparsely different (defined later) between the two populations.

2 Related Work

Decision-making is complex when multiple treatment options are present, as most evidence is represented through Average Treatment Effect (ATE). In various applications, such as precision medicine, distinct patient subgroups are expected to show different responses to treatments, necessitating an understanding of HTE. To improve the evidence quality regarding HTE, we aim to merge multiple data sources. However, integrating diverse data sources poses challenges, as data often come from populations with differing covariate distributions, treatment versions, or unmeasured confounders, resulting from design choices or unmeasured inter-study biases. Consequently, conclusions drawn from one study might not directly apply to another population without making certain assumptions about the underlying causes of population differences. We first introduce necessary notation in this section. Afterward, we discuss the commonly adopted assumptions when integrating data and explore their potential limitations.

2.1 Notation

The observed outcome Y^{obs} , covariate vector $X \in \mathcal{X}^s$, and treatment $A \in \mathcal{A} = \{a_1, \dots, a_T\}$ (treatment options) of study population $s \in \{r, o\}$ ($r = \text{RCT}, o = \text{OS}$) have density:

$$\begin{aligned} \mathbb{P}^s(Y^{\text{obs}}, X = x, A = a) &= \mathbb{P}^s(Y(a), X = x, A = a) \\ &= \mathbb{P}^s(Y(a) \mid X = x, A = a) \mathbb{P}^s(a \mid X = x) \mathbb{P}^s(X = x) \\ &= \mathbb{P}(Y(a) \mid X = x, A = a, S = s) \mathbb{P}(A = a \mid X = x, S = s) \mathbb{P}(X = x \mid S = s) \end{aligned} \quad (1)$$

where $Y(a)$ is the potential outcome for treatment $A = a$ and the last equation makes the dependence of distributions on the study s explicit. We consider combination of an OS ($s = o$)

Table 1: Notations and Definitions.

| Symbol | Description |
|---------------|--|
| A | $A \in \{-1, 1\}$ treatment indicator; 1 is for treatment |
| Y | Observed outcome of interest |
| S | $S \in \{r, o\}$ study indicator; r : RCT, o : observational |
| p | Number of measured covariates in both studies |
| X^s | Covariates observed in study $S = s$ where $X^s \in \mathcal{X}^s \subseteq \mathbb{R}^{p^s}$ |
| n^s | Size of study $S = s$ |
| τ^s | Average Treatment Effect (ATE) of population s ; $\tau^s \triangleq \mathbb{E}^s[Y(+1) - Y(-1)]$ |
| $\mu_a^s(x)$ | Conditional potential outcome mean in study s ; $\mu_a^s(x) \triangleq \mathbb{E}^s[Y(a) X = x]$ |
| $\mu^s(x, a)$ | Conditional outcome mean (regression function) in study s $\mu^s(x, a) \triangleq \mathbb{E}^s[Y X = x, A = a]$ |
| $\tau^s(x)$ | Conditional ATE in the study population s $\tau^s(x) \triangleq \mathbb{E}^s[Y(+1) - Y(-1) X = x] = \sum_a a \mu_a^s(x)$ |
| $\pi_a^s(x)$ | Treatment assignment function in study s ; $\pi_a^s(x) \triangleq \mathbb{P}^s(A = a X = x)$ Note that $\pi_{+1}^s(x) = (1 - \pi_{-1}^s(x))$ |
| $\mu^s(x)$ | CounterFactual Average Covariate Effect (CFACE) in population s $\mu^s(x) \triangleq \pi_{+1}^s(x) \mu_{-1}^s(x) + \pi_{-1}^s(x) \mu_{+1}^s(x) = \sum_a \pi_{-a}^s(x) \mu_a^s(x)$ |

with an RCT ($s = r$) to estimate the CATE of treatment a compared with a' defined as $\tau^s(x) = \mathbb{E}_{\mathbb{P}^s}[Y(a) - Y(a') | X = x]$. The goal of integration can be the improvement of causal effect estimation in either o or r populations.

2.2 Assumptions

Most methods for transportability focus on mitigating changes in covariate distribution ($\mathbb{P}^r(x) \neq \mathbb{P}^o(x)$) across studies, while assuming the invariance of some component of the outcome model based on one of the following assumptions:

1. **CATE invariance** ($\tau^r(x) = \tau^o(x)$): Assumes that the causal effects for subgroups are invariant.
2. **Mean exchangeability** ($\forall a : \mu_a^r(x) = \mu_a^o(x)$): Assumes that the potential outcome model for each treatment arm is invariant across populations.
3. **Trial participation ignorability** ($Y(A), Y(A') \perp S | X$): Assumes that units are not preferentially selected to participate in studies based on their potential outcomes.

Assumptions are listed in order of their strength, with the weaker ones being derivable from the stronger ones. It is worth noting that the strongest assumption, trial participation ignorability, is equivalent to “no outcome shift,” meaning $\mathbb{P}^r(Y(a) | X = x, A = a) = \mathbb{P}^o(Y(a) | X = x, A = a)$. Essentially, all of the mainstream assumptions can be derived from the no outcome shift assumption. However, we argue that this assumption is not realistic, and by providing methods that relax it, we lay the foundation for further relaxing other assumptions.

Transportability of the outcome model depends on the similarities between populations in terms of effect modification, treatment versions, and interference between units [11]. Addressing interference, including changes in the interference pattern, poses a significant challenge in general [12]. Assuming no interference, controlling for the shift in known (measured) effect modifiers and treatment versions is possible but complicated. However, if there are unmeasured effect modifiers [13] and/or treatment versions [14], they can lead to outcome shift between the populations. For example, differences in outcome models between RCTs and OS can be attributed to factors such as higher fidelity of the intervention in RCTs (e.g., providers in the RCT being more stricter in the application of the treatment), the Hawthorne effect (participants in trials may behave differently due to being monitored), or participation bias (certain socioeconomic groups being more likely to participate, with socioeconomic status not being recorded in the OS). While data integration frameworks have accounted for the shift in covariate distributions across studies, they often overlook potential shifts in patient outcomes caused by unmeasured variations between studies. Our aim is to extend the current integration framework by relaxing this assumption.

3 Methods for Borrowing Strength from OSs

Under SUTVA ($Y_i^{\text{obs}} = Y_i(A_i)$) and conditional ignorability ($Y(-1), Y(+1) \perp A \mid X$) we have the following ‘‘Outcome Mean Decomposition’’ for each population:

$$\mathbb{E}(Y \mid X, A) = \mathbb{E}(Y(A) \mid X) = \mu(X) + \{(1 + A)\pi_{+1}(X) - (1 - A)\pi_{-1}(X)\} \tau(X)/2, \quad (2)$$

For example, in an RCT with $\pi_{+1}^r(x) = \pi_{-1}^r(x) = 1/2$ the decomposition simplifies to $\mu^r(X, A) = \mu_A^r(X) = \mu^r(X) + \frac{A}{2}\tau^r(X)$. Since the treatment A is not present in the CFACE definition, $\mu(X)$, it is also known as **treatment-free** or **main** effect. Guided by the above decomposition, we propose an unbiased CATE estimator for the RCT, that contains a nuisance parameter $m(x)$, which if appropriately set to $\mu^r(x)$, yields minimized variance for estimated $\tau^r(X)$.

3.1 General Framework

First, we can show that the population CATE is the minimizer of the following objective.

Proposition 1. Assume SUTVA, conditional ignorability, and positivity ($\forall X, A : \pi_A(X) > 0$) hold. Then, for arbitrary $m(X)$ and $\pi_A(X)$ functions, the minimizer of below objective $\mathcal{L}(f)$ is CATE:

$$\tau(X) = \underset{f}{\operatorname{argmin}} \mathcal{L}(f), \quad \mathcal{L}(f) \triangleq \mathbb{E} \left[\left(\frac{A(Y - m(X))}{\pi_A(X)} - f(X) \right)^2 \right], \quad (3)$$

In objective (3), although both $m(X)$ and $\pi_A(X)$ are arbitrary, the latter is fixed in RCTs. Therefore, we have the freedom to select an $m(\cdot)$ to minimize the estimated CATE’s variance. Similar objective functions have been proposed in [15]. Setting $m(X) := \mu(X)$ will result in the most efficient CATE estimate:

Theorem 1. Setting $m(X) := \mu(X)$ results in the most efficient CATE estimate in (3). In other words, CFACE minimizes the CATE variance:

$$\mu(X) = \underset{m}{\operatorname{argmin}} \mathbb{V}(\tau(X)), \quad \mathbb{V}(\tau(X)) = \mathbb{E} \left[\frac{A^2(Y - m(X))^2}{\pi_A^2(X)} \mid X \right] - \tau^2(X).$$

Proof. Only the first term of variance depends on $m(X)$. First order condition implies $\mathbb{E}_{A,Y}((Y - m)/\pi_A^2) = 0$, which becomes $\mathbb{E}_A[\pi_A^{-2}(X)\mathbb{E}_Y[Y \mid X, A] \mid X] = m(X)\mathbb{E}_A[\pi_A^{-2}(X) \mid X]$. Replacing the potential outcomes in the LHS and expanding the expectation in the RHS, results in the following formula for the optimal $m(\cdot)$:

$$\frac{1}{\pi_{+1}(X)} \mathbb{E}[Y(1) \mid X] + \frac{1}{\pi_{-1}(X)} \mathbb{E}[Y(-1) \mid X] = m(X) \frac{1}{\pi_{+1}(X)\pi_{-1}(X)}$$

Solving for $m(X)$ completes the proof. \square

3.1.1 Proposed CATE Estimator in the RCT

We instantiate above results for the RCT data where ignorability and positivity hold by design. The plug-in estimator of $\tau^r(x)$ is: $\hat{\tau}^r(x^r) = \underset{f}{\operatorname{argmin}} \frac{1}{n^r} \sum_{i=1}^{n^r} \left[\frac{A_i^r(Y_i^r - m(X_i^r))}{\pi_{A_i^r}^r(X_i^r)} - f(X_i^r) \right]^2$. A special case where $f(\cdot)$ is linear and $m(X) = 0$ was proposed in [16]. To minimize $\mathbb{V}(\hat{\tau}^r(X))$, guided by the above efficiency discussion, it is tempting to set $m(\cdot)$ to the plug-in estimator of $\mu^r(\cdot)$, i.e., $m(x) := \hat{\mu}^r(x) = \sum_a \pi_{-a}^r(x) \hat{\mu}_a^r(x)$ where $\hat{\mu}_a^r(x)$ is the estimate of the regression function $\mu_a^r(x)$. But since the RCT is generally limited in sample size, we hope that the CFACE estimated from OS reduces $\mathbb{V}(\hat{\tau}^r(X))$ more than the CFACE estimated from the RCT. So, we propose,

$$m(x) := \hat{\mu}^r(x^r) \triangleq \sum_{a \in \{-1, +1\}} \pi_{-a}^r(x^r) \times \hat{\mu}^o(x^r, a), \quad (4)$$

where $\hat{\mu}^o(\cdot, a) : \mathbb{R}^p \rightarrow \mathbb{R}$ is the mean outcome function estimated from OS but applied to covariates of RCT. Note that here we have abused the notation a little because in CFACE definition, Table 1, all quantities are from the same study s but here, the treatment assignment probabilities are coming from RCT and the outcome means are computed from OS and we use the r superscript to emphasize that the final mixture is applied to data of RCT, x^r .

3.1.2 Identifiability Assumptions

Unbiased CATE estimation using 3 only requires SUTVA, positivity, and conditional ignorability. Since we instantiate 3 with RCT data, treatment randomization ensures conditional ignorability. Thus, our general framework’s essential assumptions are SUTVA and positivity, considered minimal in causal inference literature. Note that correct specification of outcome models $\mu^o(\cdot, a)$ and subsequently CFACE $\mu^r(\cdot)$ are not necessary, i.e., if $m(x)$ is misspecified or inaccurately estimated, only the variance reduction gain will be smaller.

3.2 Outcome Shift

So far, we have not assumed any relationship between the joint distributions $\mathbb{P}^r(X, Y, A)$ and $\mathbb{P}^o(X, Y, A)$. Going back to the factorization 1, we observe that from the three factors $\mathbb{P}^s(Y(a) | X = x, A = a)$, $\mathbb{P}^s(a | X = x)$, and $\mathbb{P}^s(X = x)$ only the former is of our concern in (4). The treatment assignment probability in (4) is from an RCT and is thus known; the covariate distribution is irrelevant mainly because we are interested in CATE estimation and any shift in $\mathbb{P}^s(X = x)$ only changes the ATE. So assuming no outcome shift $\mathbb{P}^r(Y(a) | X = x, A = a) = \mathbb{P}^o(Y(a) | X = x, A = a)$ and no unmeasured confounders in the OS ($\hat{\mu}_a^o(\cdot) = \hat{\mu}^o(\cdot, a)$) proves that the proposed value for $m(X)$ is indeed the plug in estimator for CFACE. In such a case, we can even add the RCT data to the OS data and learn only one outcome function per treatment and estimate CFACE with even more samples. But for reasons explained in Section (2.2), “no outcome shift” is not a realistic assumption. Here we relax this assumption by allowing the *mean* of the two potential outcome distributions to be different in a structured manner.

3.2.1 Sparse Outcome Shift

Here, we assume a working model that posits linearity of potential outcome means $\mu_a^s(x)$, which implies linearity of CATE, CFACE, and $f(\cdot)$ in (3). Although this is a parametric assumption, we note that our techniques are generalizable to nonlinear forms through basis function methods. Even if linearity is violated, our approach still results in interpretable parameter estimates even though it utilizes a linear structure for the outcome model. We demonstrate in our numerical experiments that our proposed methods can improve estimation even when the linearity assumption is violated. Further, in contrast to most of the previous works, we do not assume trial participation ignorability, i.e., $\tau^r(x) \neq \tau^o(x)$. But we assume that the change in outcome means between studies is sparse. In other words, the outcome means of two studies are $\mu^o(x, a) = \gamma_a^{oT} x$ and $\mu^r(x, a) = \mu_a^{rT} x = \gamma_a^{rT} x = (\gamma_a^o + \delta_a)^T x$, where δ_a s are sparse. Sparse outcome shift has been previously proposed as a framework for multi-task learning [17, 18]. Finally, without loss of generality, we assume RCT being fully randomized: $\pi_a^r(x^r) = \pi_a^r$. In this notation, the two CATEs are, $\tau^r(x) = \sum_a a \gamma_a^{rT} x = \sum_a a (\gamma_a^o + \delta_a)^T x \neq \sum_a a \gamma_a^{oT} x = \tau^o(x)$. The objectives for learning the CFACE and CATE become:

$$\hat{\gamma}_a^o = \underset{\gamma}{\operatorname{argmin}} \frac{1}{n_a^o} \sum_{i=1}^{n_a^o} \mathbb{1}(A_i^o = a) \left[Y_i^o - \gamma^T X_i^o \right]^2 + \lambda_{1a} \|\gamma\|_1 \quad (5)$$

$$\left(\tilde{\delta}_{-1}^r, \tilde{\delta}_{+1}^r \right) = \underset{(\delta_{-1}, \delta_{+1})}{\operatorname{argmin}} \frac{1}{n_a^r} \sum_{i=1}^{n_a^r} \mathbb{1}(A_i^r = a) \left[Y_i^r - (\hat{\gamma}_a^o + \delta_a)^T X_i^r \right]^2 + \sum_a \lambda_{2a} \|\delta_a\|_1, \hat{\gamma}_a^{r,c} \triangleq \hat{\gamma}_a^o + \tilde{\delta}_a^r \quad (6)$$

$$\hat{\delta}^r = \underset{\delta}{\operatorname{argmin}} \frac{1}{n^r} \sum_{i=1}^{n^r} \left[\frac{A_i^r}{\pi_{A_i^r}^r} \left(Y_i^r - \sum_a \pi_{-a}^r \hat{\gamma}_a^{rT} X_i^r \right) - (\hat{\gamma}_{+1}^{r,c} - \hat{\gamma}_{-1}^{r,c} + \delta)^T X_i^r \right]^2 + \lambda_3 \|\delta\|_1 \quad (7)$$

where $\mathbb{1}(\cdot)$ is the indicator function, $\sum_a \pi_{-a}^r (\hat{\gamma}_a^o + \tilde{\delta}_a^r)^T x_i^r$ in (7) is the estimated (suggested in (4)) and calibrated CFACE, and the l_1 -norm penalization induces sparsity. Note that in (6) and (7) we estimate separate deltas for $m(x)$ and $\tau(x)$ to make the results robust to model misspecification. We call step (6) *calibration of OS’s outcome models to the RCT*. The overall estimate of the CATE is then $(\hat{\gamma}_{+1}^o + \tilde{\delta}_{+1}^r - [\hat{\gamma}_{-1}^o + \tilde{\delta}_{-1}^r] + \hat{\delta}^r)^T x^r$. The purpose of (5) is to provide a preliminary estimate of the CFACE in the OS; the purpose of (6) is to calibrate the OS estimate of the CFACE to the RCT data. This calibration also results in the following preliminary estimate of the CATE that is calibrated to the RCT data under the sparsely different assumption: $(\hat{\gamma}_{+1}^o + \tilde{\delta}_{+1}^r - [\hat{\gamma}_{-1}^o + \tilde{\delta}_{-1}^r])^T x^r$. If this preliminary CATE estimate is a good estimate of the CATE in the RCT data, the final objective

function is redundant (7). The objective in (7) leverages the observation data in two ways: first, it uses the calibrated CFACE estimate to reduce variance in estimating the CATE for the RCT population and secondly, it also benefits from a preliminary estimate of the CATE in $\hat{\gamma}_{+1}^o + \tilde{\delta}_{+1}^r - [\hat{\gamma}_{-1}^o + \tilde{\delta}_{-1}^r]$; if this preliminary estimate is good, then all or most components in $\hat{\delta}^r$ will be penalized to zero. If this estimate is not perfect, but still approximates the CATE well, then the $\hat{\delta}^r$ will correct for any such poor approximation. Thus, the observational data is used in two ways and the final step allows for flexible borrowing of information from the preliminary CATE estimate, thereby reducing variance.

3.2.2 Theoretical Justification

Analysis without Calibration. Assuming that the outcome model is consistently estimated in (5), and skipping the calibration step and estimating the δ vectors directly along with CATE, the theoretical justification of the method becomes straightforward. In this case, the counterpart of (7) corresponds to two separate LASSO regressions, as discussed in Appendix 6.1. Under the assumption of correctly specified models, the separated LASSO regression will recover the sparse mean shifts, benefiting from the theoretical guarantees of regular LASSO [19].

Misspecification, Calibration, and Interpretability. It is important to note that under model misspecification (e.g., when the true outcome model is not linear or the shift is not sparse), the performance of the method may suffer. To address this, we propose the use of the calibration step in (6), where the δ_a vectors are initially trained to better explain the variance of the RCT outcome, resulting in a better $m(X)$ for the CATE estimation (7) step where a separate δ parameter is used for capturing CATE variation between populations. It is crucial to emphasize that our primary goal is to accurately and efficiently estimate the CATE in the RCT.

Finally, by adhering to the linear model, we make a theoretically grounded tradeoff between interpretability and flexibility. For instance, similar to recent works [20], we can demonstrate that (7) estimates a linear projection of the true (possibly non-linear) CATE. Consequently, our estimated linear CATE remains interpretable, irrespective of the linearity of the true CATE.

Cross-fitting. Conducting both steps, (6) and (7), using the same data from the RCT may give rise to theoretical challenges (e.g., harder consistency or prediction error analysis) as well as practical issues (e.g., overfitting). To mitigate these problems, one solution is to perform estimation in each step using independent sets of samples [21]. In the causal inference literature, this is achieved through cross-fitting [22]. Here, we divide the RCT data into K folds and employ one fold for calibration step (6) and $K - 1$ folds for CATE estimation of (7). The final δ vector required for CATE estimation is obtained by averaging all $\hat{\delta}^r$ vectors estimated as solutions of (7) across the K rounds of cross-fitting.

4 Experiments

We run a series of thorough simulations to test how our proposed methods perform under various conditions. First, we look into the effect of sample splitting on our methods. Our results show that our approach works consistently well, whether we use sample splitting or not. Although the former is easier to justify theoretically, the latter is more efficient computationally. Next, we evaluate how model misspecification impacts CATE estimation. Even when the true outcome model is not strictly linear, our findings show that our method, which uses OS data, still performs strongly. This is especially clear when compared to a non-linear CATE estimators that only use RCT data. Finally, we examine the influence of unobserved effect modifiers affect CATE estimation.

4.1 Data Simulated Based on the Proposed Model

For all simulations, potential outcomes are generated (one model for each treatment arm) following the described models. We calculate the true CATE, then generate the observed outcomes by obscuring the unobserved potential outcome according to the treatment assignment.

Simulated OS Data. To generate simulated data for each arm of the OS, we perform:

- **Covariate Generation:** We generate a covariate vector, $x \in \mathbb{R}^{100}$, from a zero mean multivariate normal distribution with a dense covariance matrix (all off-diagonal elements are non-zero).

Table 2: CATE Estimation using Data Simulated Based on the Proposed Model.

| Number of Samples per Study | | | |
|-----------------------------------|-------------------------|-----------------|-----------------|
| n_r | 250 | 500 | 1,000 |
| n_o | 10,000 | 10,000 | 10,000 |
| Method | RMSE of CATE Estimation | | |
| RCT only (Naive) | 1.50 ± 0.40 | 1.20 ± 0.30 | 0.88 ± 0.25 |
| CFACE from RCT | 0.32 ± 0.04 | 0.22 ± 0.03 | 0.15 ± 0.02 |
| CFACE from OS (Proposed) | 0.16 ± 0.02 | 0.11 ± 0.02 | 0.08 ± 0.01 |
| CFACE from OS (Proposed - Robust) | 0.16 ± 0.03 | 0.11 ± 0.02 | 0.08 ± 0.01 |
| Proposed - Robust, Cross Fitted | 0.18 ± 0.04 | 0.12 ± 0.02 | 0.09 ± 0.01 |

- **Arm-specific Outcome Simulation:** For each arm a , we simulate the outcome $y^o(a)$ using the equation $y^o(a) = \langle \beta_a^o, x^o \rangle + \epsilon$. Here, β_a^o represents the true coefficients associated with arm a , x^o is the covariate vector for the given sample, and ϵ is a random noise term. The size of the randomly selected support of β_a^o is 10. The values of these non-zero elements are sampled from the interval $\text{Uniform}(-2/3, -1/3) \cup \text{Uniform}(1/3, 2/3)$. The noise term ϵ is drawn from $N(0, 1/9)$.
- **Treatment Assignment Probabilities:** To determine the probabilities $\pi_1^o(x)$ of assigning treatment, we employ a logistic model that uses ten randomly chosen covariates. The model includes an intercept term, which is adjusted such that at least one-third of the samples receive the treatment.

Simulated RCT Data. To simulate the RCT population, we introduce domain and outcome shifts:

- **Covariate Shift:** We shift the mean of the multivariate distribution of covariates. Specifically, we randomly select 10 covariates (elements of x^r) and shift their means from zero by adding values sampled from the interval $\text{Uniform}(-1/2, -1/4) \cup \text{Uniform}(1/2, 1/4)$.
- **Outcome Shift:** We also introduce a shift in the mean of the outcome models $y^r(a) = \langle \beta_a^r, x^r \rangle + \epsilon$. For each treatment arm a , we select two random elements of β_a^r and perturb them by adding values randomly sampled from the interval $\text{Uniform}(-1, -1/2) \cup \text{Uniform}(1/2, 1)$. The noise term ϵ is drawn from $N(0, 1/9)$.
- **Treatment Assignments:** Treatment assignments are made randomly with $\pi_1^r(x) = 1/2$.

Methods. The simulations are conducted with a fixed number of OS samples $n_o = 10,000$, while the number of RCT samples varies. Table 2 presents the results of the simulation, where we compute the mean and standard deviation of the RMSE of CATE estimation based on 100 independent runs of the simulation and estimation methods. Four models are compared in terms of their performance:

- **RCT Only (Naive):** This model employs a LASSO regression that solely utilizes the RCT data to fit the outcome of each treatment arm. The CATE $\tau(x)$ is computed by taking the contrast of them.
- **CFACE with RCT Data:** This method adopts the formulation proposed in (3) and computes the CFACE $m(X)$ using the potential outcome means computed from the RCT data using the LASSO.
- **Proposed Method:** This approach estimates the OS outcome means using (5), but does NOT calibrate them and estimates the CATE using (11). All steps employ LASSO regularization.
- **Proposed - Robust Method:** This approach estimates the OS outcome means using (5), calibrates them to the RCT outcomes using (6), and estimates the CATE using (7). All steps employ LASSO.
- **Cross-Fitted Proposed Method:** The last row of the table corresponds to the cross-fitting version of the proposed method. In this variant, the outcome means are learned from the OS data using (5), while the RCT data is divided into five folds. Each fold is used once for the calibration step of (6), while the remaining folds are used for CATE estimation in (7). The final δ vector (parts of the CATE coefficients) is computed as the average of the five cross-fitted δ vectors.

All LASSO regressions are cross-validated using `cv.glmnet()` using the default parameters [23].

Results and Discussion. Table 2 presents the results of the experiments, showing the performance of different methods in estimating the CATE. It is evident that as the number of RCT samples increases, the estimation performance improves for all methods. However, it is important to note that even with $n_r = 1,000$, the first two methods that do not utilize information from the large OS dataset perform worse compared to the proposed methods with $n_r = 250$. Among these two methods, the

Naive model exhibits notably inferior performance, highlighting the efficiency gain achieved by incorporating $m(X)$ regardless of the data used for its estimation.

The cross-fitted version of the proposed method shows a slightly worse RMSE compared to the non-cross-fitted version. However, the difference is negligible. Considering the increased computational time required for cross-fitting, we omit it in subsequent experiments and focus on evaluating our method without sample splitting. Overall, the results indicate that the proposed method, which leverages both the OS and RCT data, offers significantly improved CATE estimation compared to the methods that rely solely on RCT data and do not utilize OS information.

4.2 Data Simulated from a Misspecified Model

To assess the robustness of the proposed method in the presence of misspecification, we introduce modifications to the outcome mean simulation. Specifically, we incorporate a scaled sine function to the contribution of each effect modifier. If a feature x_j is an effect modifier (i.e., $\beta_a^s(j)$ is non-zero), we modify its contribution to the outcome as $\beta_a^s(j)x_j + m_a^s x_j^2$, where m is randomly sampled from $\text{Uniform}(0.25, 0.5)$, for arm a of the study population s .

We compare four methods: Naive RCT, CFACE computed from RCT, the proposed method, and its robust variant. In this experiment, we make the core methods of the two baseline approaches nonlinear by employing cross-validated random forest [24] to estimate outcomes and CFACE. On the other hand, despite being misspecified in this context, the proposed methods continue to utilize LASSO regression, operating under the assumption of a linear model and sparse outcome shift.

Figure 1a displays the average simulation results obtained by fixing the number of OS samples at $n_o = 10,000$ and varying the number of RCT samples between 250 and 2,000. Each experiment was repeated 30 times. Notably, both of our misspecified models, which incorporate information from the large OS, outperform the two methods that rely solely on RCT data. Additionally, our robust model that includes a calibration step outperforms its non-robust counterpart. It is important to note that even with a small number of RCT samples, the use of CFACE enhances the performance of the Naive RCT model. Furthermore, as expected, the performance of all methods is reduced due to the misspecification, as can be compared with the rows of Table 2




Figure 1: CATE estimation accuracy under various violations of trivial settings.

4.3 Effect of Unmeasured Effect Modifiers

So far, we assumed that all effect modifiers were measured in both populations. Now, we investigate the impact of unmeasured effect modifiers by removing some of these covariates from the data generated by the linear sparse outcome shift model. Specifically, we randomly remove 10% to 50% of the effect modifiers, corresponding to the removal of 1 to 8 covariates on average from the original ~ 15 effect modifiers. Figure 1b illustrates the CATE estimation performance of the four methods.

We fix the number of RCT and OS samples at 250 and 10,000, respectively. As observed, our proposed methods, which utilize a large OS dataset, outperform the other methods. However, the performance margin gradually diminishes as the number of unmeasured effect modifiers increases. Notably, even a 10% increase (equivalent to the removal of one covariate) in the number of unmeasured effect modifiers significantly worsens the CATE estimation performance for methods that

employ CFACE. Conversely, the Naive method shows a smaller change in its performance. This comparison can be made by comparing the leftmost points of curves of Figure 1b with the leftmost column of Table 2. These findings highlight the sensitivity of the efficiency gained through using CFACE to the presence of unmeasured effect modifiers.

5 Conclusion

In this paper, we introduced a novel, theoretically justified method for estimating the Conditional Average Treatment Effect (CATE), leveraging data from both observational studies (OS) and randomized controlled trials (RCT). Our extensive simulations demonstrated the superior performance of this approach compared to traditional methods that rely solely on RCT data. Importantly, our method maintains its robust performance even under conditions of model misspecification and in the presence of unmeasured effect modifiers. These findings underscore the efficiency and versatility of our approach in integrating OS and RCT data. By significantly enhancing CATE estimation, our method paves the way for more accurate, personalized decision making across a variety of fields, including healthcare and clinical research.

References

- [1] Elias Bareinboim and Judea Pearl. Causal inference and the data-fusion problem. *Proceedings of the National Academy of Sciences*, 113(27):7345–7352, 2016.
- [2] Bénédicte Colnet, Imke Mayer, Guanhua Chen, Awa Dieng, Ruohong Li, Gaël Varoquaux, Jean-Philippe Vert, Julie Josse, and Shu Yang. Causal inference methods for combining randomized trials and observational studies: a review. *arXiv preprint arXiv:2011.08047*, 2020.
- [3] Irina Degtiar and Sherri Rose. A review of generalizability and transportability. *Annual Review of Statistics and Its Application*, 10:501–524, 2023.
- [4] SJ Pocock. The combination of randomized and historical controls in clinical trials. *Journal of Chronic Diseases*, 29(3):175–188, 1976.
- [5] X Li and Y Song. Target population statistical inference with data integration across multiple sources—an approach to mitigate information shortage in rare disease clinical trials. *Statistics in Biopharmaceutical Research*, 12(3):322–333, 2020.
- [6] Y Liu, B Lu, R Foster, Y Zhang, ZJ Zhong, MH Chen, and P Sun. Matching design for augmenting the control arm of a randomized controlled trial using real-world data. *Biopharm Stat*, 32(1):124–140, 2022.
- [7] JG Ibrahim and MH Chen. Power prior distributions for regression models. *Statistical Science*, 15:46–60, 2000.
- [8] B Neuenschwander, G Capkun-Niggli, M Branson, and DJ Spiegelhalter. Summarizing historical information on controls in clinical trials. *Clinical Trials*, 7(1):5–18, 2010.
- [9] A Kaizer, JS Koopmeiners, and BP Hobbs. Bayesian hierarchical modeling based on multisource exchangeability. *Biostatistics*, 19(2):169–184, 2018.
- [10] A Kotalik, DM Vock, EC Donny, DK Hatsukami, and JS Koopmeiners. Dynamic borrowing in the presence of treatment effect heterogeneity. *Biostatistics*, 22(4):789–804, 2021.
- [11] Miguel A. Hernán and James M. Robins. *Causal Inference: What If*. Boca Raton: Chapman & Hall/CRC., 2020.
- [12] Michael G Hudgens and M Elizabeth Halloran. Toward causal inference with interference. *Journal of the American Statistical Association*, 103(482):832–842, 2008.
- [13] Xinkun Nie, Guido Imbens, and Stefan Wager. Covariate balancing sensitivity analysis for extrapolating randomized trials across locations. *arXiv preprint arXiv:2112.04723*, 2021.
- [14] Miguel A Hernán and Tyler J VanderWeele. Compound treatments and transportability of causal inference. *Epidemiology (Cambridge, Mass.)*, 22(3):368, 2011.
- [15] Menggang Yu, Chensheng Kuang, Jared D Huling, and Maureen Smith. Diagnosis-group-specific transitional care program recommendations for 30-day rehospitalization reduction. *The Annals of Applied Statistics*, 15(3):1478–1498, 2021.

- [16] James E Signorovitch. *Identifying Informative Biological Markers in High-Dimensional Genomic Data and Clinical Trials*. PhD thesis, Harvard University, 2007.
- [17] Samuel M Gross and Robert Tibshirani. Data shared lasso: A novel tool to discover uplift. *Computational statistics & data analysis*, 101:226–235, 2016.
- [18] Amir Asiaee, Samet Oymak, Kevin R Coombes, and Arindam Banerjee. High dimensional data enrichment: Interpretable, fast, and data-efficient. *arXiv preprint arXiv:1806.04047*, 2018.
- [19] Martin J Wainwright. *High-dimensional statistics: A non-asymptotic viewpoint*, volume 48. Cambridge university press, 2019.
- [20] Edward H Kennedy, Scott Lorch, and Dylan S Small. Robust causal inference with continuous instruments using the local instrumental variable curve. *Journal of the Royal Statistical Society Series B: Statistical Methodology*, 81(1):121–143, 2019.
- [21] Zhenghao Zeng, Edward H Kennedy, Lisa M Bodnar, and Ashley I Naimi. Efficient generalization and transportation. *arXiv preprint arXiv:2302.00092*, 2023.
- [22] Victor Chernozhukov, Denis Chetverikov, Mert Demirer, Esther Duflo, Christian Hansen, Whitney Newey, and James Robins. Double/debiased machine learning for treatment and structural parameters, 2018.
- [23] Jerome Friedman, Trevor Hastie, and Rob Tibshirani. Regularization paths for generalized linear models via coordinate descent. *Journal of statistical software*, 33(1):1, 2010.
- [24] Andy Liaw, Matthew Wiener, et al. Classification and regression by randomforest. *R news*, 2(3):18–22, 2002.

6 Appendix

6.1 Proposed Model: Formulation without the Calibration Step

Here, we present the instantiation of our general framework without the calibration step. This formulation is easier for theoretical analysis but has inferior performance under misspecification. In experiments, we call this model the “**proposed model**” and its alternative which utilizes the calibration step “**proposed - robust model**.”

The two objectives for learning CFACE and CATE become:

$$\hat{\gamma}_a^o = \underset{\gamma}{\operatorname{argmin}} \frac{1}{n_a^o} \sum_{i=1}^{n_a^o} \mathbb{1}(a_i^o = a) \left[y_i^o - \gamma^T x_i^o \right]^2 + \lambda_{1a} \|\gamma\|_1, \quad \gamma \in \mathbb{R}^{p+q}, \quad (8)$$

$$(\hat{\delta}_{-1}^r, \hat{\delta}_{+1}^r) = \underset{(\delta_{-1}^r, \delta_{+1}^r)}{\operatorname{argmin}} \frac{1}{n^r} \sum_{i=1}^{n^r} \left[\frac{a_i^r}{\pi_{a_i^r}^r} \left(y_i^r - \sum_a \pi_{-a}^r (\hat{\gamma}_a^o + \delta_a)^T x_i^r \right) - \sum_a a (\hat{\gamma}_a^o + \delta_a)^T x_i^r \right]^2 + \sum_a \lambda_{2a} \|\delta_a\|_1 \quad (9)$$

Note that $\sum_a \pi_{-a}^r (\hat{\gamma}_a^o + \delta_a)^T x_i^r$ is CFACE in (9).

Below, we show that the objective of (9) decomposes over treatments:

$$\begin{aligned} & \frac{1}{n^r} \sum_{i=1}^{n^r} \left[\frac{a_i^r}{\pi_{a_i^r}^r} \left(y_i^r - \sum_a \pi_{-a}^r (\hat{\gamma}_a^o + \delta_a)^T x_i^r \right) - \sum_a a (\hat{\gamma}_a^o + \delta_a)^T x_i^r \right]^2 + \sum_a \lambda_{2a} \|\delta_a\|_1 \quad (10) \\ &= \frac{1}{n^r} \sum_{i=1}^{n^r} \left[\frac{a_i^r}{\pi_{a_i^r}^r} y_i^r - \left(\sum_a \left[a_i^r \frac{\pi_{-a}^r}{\pi_{a_i^r}^r} + a \right] (\hat{\gamma}_a^o + \delta_a)^T \right) x_i^r \right]^2 + \sum_a \lambda_{2a} \|\delta_a\|_1 \\ &= \frac{1}{n^r} \sum_a \sum_{i=1}^{n^r} \mathbb{1}(a_i^r = a) \left[\frac{a}{\pi_a^r} y_i^r - a(1 + \alpha^a) (\hat{\gamma}_a^o + \delta_a)^T x_i^r \right]^2 + \lambda_{2a} \|\delta_a\|_1 \end{aligned}$$

where $\alpha \triangleq \frac{\pi_{-1}^r}{\pi_{+1}^r}$, $\mathbb{1}(\cdot)$ is the indicator. This careful simplification of (9) shows that the objective is separable for δ_a s as:

$$\hat{\delta}_a^r = \underset{\delta_a}{\operatorname{argmin}} \frac{1}{n_a^r} \sum_{i: a_i^r = a} \left[\left(\frac{a}{\pi_a^r} y_i^r - a(1 + \alpha^a) \hat{\gamma}_a^{o^T} x_i^r \right) - a(1 + \alpha^a) \delta_a^T x_i^r \right]^2 + \lambda_{2a} \|\delta_a\|_1, \quad (11)$$

where n_a^r is the number of samples in RCT where $A = a$. Note that (11) is an L_1 -regularized regression using data of each treatment a to estimate δ_a . Here, the estimated CFACE and CATE are $\hat{\mu}^r(x) = \sum_a \pi_{-a}^r \hat{\gamma}_a^{o^T} x$ and $\hat{\tau}^r(x) = \sum_a a (\hat{\gamma}_a^o + \hat{\delta}_a)^T x$.